Related Experiment Video

Updated: Jul 10, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling

Ramin Massoumi1, Katarzyna Chmielarska, Katharina Hennecke

  • 1Department of Molecular Medicine, Max Planck Institute of Biochemistry, D-82152 Martinsried, Germany.

Cell
|May 23, 2006
PubMed

Insights

The CYLD gene deubiquitinase regulates skin tumor growth by controlling different NF-kappaB pathways. Loss of CYLD increases susceptibility to chemically induced skin tumors by affecting cell proliferation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Dermatology

Background:

  • Mutations in the CYLD gene are linked to hair-follicle keratinocyte tumors.
  • The CYLD gene encodes a deubiquitinase enzyme involved in regulating cellular signaling pathways.
  • CYLD deubiquitinase activity targets lysine 63-linked ubiquitin chains on TRAF2, inhibiting p65/p50 Nuclear Factor-kappaB (NF-kappaB) activation.

Purpose of the Study:

  • To investigate the role of the CYLD gene in chemically induced skin tumorigenesis.
  • To elucidate the specific NF-kappaB pathways regulated by CYLD in keratinocytes.
  • To understand how CYLD inactivation contributes to skin tumor development and proliferation.

Main Methods:

  • Utilized Cyld knockout (Cyld-/-) mice to assess susceptibility to chemically induced skin tumors.
  • Analyzed Cyld-/- tumors and keratinocytes treated with 12-O-tetradecanoylphorbol-13 acetate (TPA) or UV light for hyperproliferation and cyclin D1 levels.
  • Investigated the nuclear translocation and deubiquitination activity of CYLD in relation to Bcl-3 and NF-kappaB components (p50, p52).

Main Results:

  • Mice lacking Cyld (Cyld-/-) exhibited high susceptibility to chemically induced skin tumors.
  • Cyld-/- tumors and treated keratinocytes showed hyperproliferation and elevated cyclin D1 levels.
  • CYLD inactivation led to increased nuclear activity of Bcl-3-associated NF-kappaB p50 and p52, driving proliferation, rather than affecting p65/p50 action.

Conclusions:

  • CYLD negatively regulates distinct NF-kappaB pathways based on external signals.
  • Inactivation of TRAF2 by CYLD influences survival and inflammation.
  • Inhibition of Bcl-3 by CYLD controls cell proliferation and tumor growth, highlighting CYLD's critical role in preventing skin tumorigenesis.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...